Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Papillary thyroid cancer: New markers offer hope for tailored treatment

2.

Belantamab Mafodotin: The Comeback Drug in Multiple Myeloma

3.

Modified personalized cancer vaccine generates powerful immune response

4.

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

5.

Children living near oil and gas wells face higher risk of rare leukemia, studies show


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot